ATE469173T1 - Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung - Google Patents

Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung

Info

Publication number
ATE469173T1
ATE469173T1 AT07843791T AT07843791T ATE469173T1 AT E469173 T1 ATE469173 T1 AT E469173T1 AT 07843791 T AT07843791 T AT 07843791T AT 07843791 T AT07843791 T AT 07843791T AT E469173 T1 ATE469173 T1 AT E469173T1
Authority
AT
Austria
Prior art keywords
pth
pegylated
receptor modulators
pth receptor
mammal
Prior art date
Application number
AT07843791T
Other languages
German (de)
English (en)
Inventor
Patricia Lea Brown-Augsburger
Wayne David Kohn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE469173T1 publication Critical patent/ATE469173T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Input Circuits Of Receivers And Coupling Of Receivers And Audio Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07843791T 2006-10-13 2007-10-04 Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung ATE469173T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82938306P 2006-10-13 2006-10-13
PCT/US2007/080367 WO2008048784A1 (en) 2006-10-13 2007-10-04 Pegylated pth as pth receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
ATE469173T1 true ATE469173T1 (de) 2010-06-15

Family

ID=42828673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07843791T ATE469173T1 (de) 2006-10-13 2007-10-04 Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung

Country Status (16)

Country Link
US (1) US7820179B2 (https=)
EP (1) EP2084183B1 (https=)
JP (1) JP5200027B2 (https=)
KR (1) KR101108354B1 (https=)
CN (1) CN101522709B (https=)
AT (1) ATE469173T1 (https=)
AU (1) AU2007313001B2 (https=)
BR (1) BRPI0719885B8 (https=)
CA (1) CA2672907C (https=)
DK (1) DK2084183T3 (https=)
EA (1) EA014696B1 (https=)
MX (1) MX2009003740A (https=)
NO (1) NO341986B1 (https=)
PL (1) PL2084183T3 (https=)
SI (1) SI2084183T1 (https=)
WO (1) WO2008048784A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
MY208384A (en) * 2016-03-01 2025-05-05 Ascendis Pharma Bone Diseases As Pth prodrugs
US12453778B2 (en) 2016-09-29 2025-10-28 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
KR102627405B1 (ko) * 2016-09-29 2024-01-18 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
HRP20230383T1 (hr) * 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
MY209748A (en) 2019-02-11 2025-07-31 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2550204B1 (fr) 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
JPS6360940A (ja) 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
EP0293158A3 (en) 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroid hormone antagonists
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
JPH0532696A (ja) 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
JPH05271279A (ja) 1991-08-07 1993-10-19 Takeda Chem Ind Ltd ヒト副甲状腺ホルモンムテインおよびその製造法
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US6110892A (en) 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
DK0915911T3 (da) 1996-08-02 2004-03-08 Ca Nat Research Council Analoger til parathyreoideahormon til behandling af osteoporose
HUP0003349A3 (en) 1997-05-14 2001-12-28 Aventis Pharmaceuticals Inc Co Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use
EP1030658A1 (en) * 1997-10-14 2000-08-30 Eli Lilly And Company Method of building and maintaining bone
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CZ20003798A3 (cs) 1998-04-15 2001-08-15 Aventis Pharmaceuticals Products, Inc. Způsob výroby cyklických peptidů vázaných k polymernímu nosiči
US7531621B1 (en) 1998-05-05 2009-05-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. PTH2 receptor selective compounds
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US7022815B1 (en) 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
WO2001023521A2 (en) 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
EP1477496A4 (en) * 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd PEG-CONJUGATED PTH BZW. PEG-CONJUGATED PTH DERIVATIVE
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
TW533925U (en) 2002-09-26 2003-05-21 Lee Yeong Ind Co Ltd Improvement of speed-changing transmission mechanism for cutting tools of drill sharpening machine
CA2511966A1 (en) 2002-11-01 2004-07-22 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
WO2004084918A1 (ja) * 2003-03-25 2004-10-07 Sekisui Chemical Co., Ltd. 皮膚止痒外用組成物
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
EP1758927A4 (en) 2004-01-21 2008-09-17 Unigene Lab Inc PARATHYROID HORMONE AMIDE FRAGMENTS AND USES THEREOF

Also Published As

Publication number Publication date
NO20091691L (no) 2009-05-11
EP2084183A1 (en) 2009-08-05
US20090253630A1 (en) 2009-10-08
CA2672907A1 (en) 2008-04-24
BRPI0719885B8 (pt) 2021-05-25
AU2007313001B2 (en) 2012-03-22
CN101522709B (zh) 2013-03-20
MX2009003740A (es) 2009-04-22
PL2084183T3 (pl) 2010-10-29
BRPI0719885A2 (pt) 2014-04-29
US7820179B2 (en) 2010-10-26
AU2007313001A1 (en) 2008-04-24
JP5200027B2 (ja) 2013-05-15
SI2084183T1 (sl) 2010-09-30
KR20090067168A (ko) 2009-06-24
DK2084183T3 (da) 2010-08-16
CA2672907C (en) 2013-08-06
EA200970376A1 (ru) 2009-10-30
EA014696B1 (ru) 2010-12-30
EP2084183B1 (en) 2010-05-26
JP2010506844A (ja) 2010-03-04
WO2008048784A1 (en) 2008-04-24
CN101522709A (zh) 2009-09-02
KR101108354B1 (ko) 2012-01-25
NO341986B1 (no) 2018-03-12
BRPI0719885B1 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
ATE469173T1 (de) Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung
NO20083011L (no) Modulatorer av muskarine receptorer
DK2059243T3 (da) Buprenorphin-vaffel til lægemiddelsubstitutionsterapi
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EP1895931A4 (en) DENTAL RESTORATION SYSTEM AND COMPONENTS
ATE469895T1 (de) Cgrp-rezeptorantagonisten
NO20071272L (no) Modulatorer av muskarine reseptorer.
IL193479A0 (en) Modulators of muscarinic receptors
CA2645871A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EP1898827A4 (en) DENTAL RESTORATION SYSTEM AND COMPONENTS
IL189164A0 (en) Pyrimidine compounds as serotonin receptor modulators
NO20084006L (no) Modulatorer av muskarinreseptorer
EP1940800A4 (en) INNOVATIVE BICYCLIC SULFONAMIDES AS MODULATORS OF GLUCOCORTICOID RECEPTOR IN THE TREATMENT OF INFLAMMATORY DISEASES
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2009003981A (es) Agentes moduladores del receptor de calcio.
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
EP2102231A4 (en) IMPROVED EXPRESSION SYSTEM FOR RECOMBINANT HUMAN ARGINASE I
ZA200708372B (en) KIM-1 antibodies for treatment of Th2-mediated conditions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2084183

Country of ref document: EP